SBIR-STTR Award

Development of Human Monoclonal Antibody Therapeutic Against Klebsiella pneumoniae Infection
Award last edited on: 8/29/2024

Sponsored Program
SBIR
Awarding Agency
DOD : DHA
Total Award Amount
$1,348,589
Award Phase
2
Solicitation Topic Code
DHA202-003
Principal Investigator
Robert Price

Company Information

Technology Holding LLC

1515 West 2200 South Suite F
Salt Lake City, UT 84119
   (801) 953-1047
   rkm@tekholding.com
   www.tekholding.com
Location: Single
Congr. District: 02
County: Salt Lake

Phase I

Contract Number: W81XWH21P0031
Start Date: 2/10/2021    Completed: 9/9/2021
Phase I year
2021
Phase I Amount
$249,563
Antibiotic resistant infections are a principal concern for the Department of Defense and society at large due to the current lack of available treatments. Monoclonal antibodies represent a promising drug class that could be applied to antibiotic resistant infections to harness a patients own immune system to effectively combat the invading threat. In this program we present an optimized workflow to yield high affinity monoclonal antibody candidates against surface antigens from common infectious disease which is increasingly antibiotic resistant.

Phase II

Contract Number: HT9425-23-C-0005
Start Date: 2/22/2023    Completed: 7/26/2023
Phase II year
2023
Phase II Amount
$1,099,026
Antibiotic resistant infections are a principal concern for the Department of Defense and society at large due to the current lack of available treatments. Monoclonal antibodies represent a promising drug class that could be applied to antibiotic resistant infections to harness a patients own immune system to effectively combat the invading threat. In this program we continue program development to determine binding epitopes of novel antibody candidates, express candidates, and show infectivity reduction potential in in vitro and in vivo assays.